Human & Experimental Toxicology

 

Advanced Search

Journal Navigation

Journal Home

Subscriptions

Archive

Contact Us

Table of Contents

Register here to gain access to SAGE's 500+ Journals Online

Click here to sign up for SAGE Journal Email Alerts today!

Sign In to gain access to subscriptions and/or personal tools.
This Article
Right arrow Full Text (PDF)
Right arrow References
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to Saved Citations
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Request Reprints
Right arrow Add to My Marked Citations
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Tracqui, A
Right arrow Articles by Ludes, B
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Tracqui, A
Right arrow Articles by Ludes, B
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?
Human & Experimental Toxicology, Vol. 22, No. 9, 515-521 (2003)
DOI: 10.1191/0960327103ht389oa

HPLC/MS findings in a fatality involving sustained-release verapamil

A Tracqui

Institut de Médecine Légale, 11 rue Humann, 67085 Strasbourg Cedex, France; atracqui{at}mageos.com

C Tournoud

Service de Réanimation Médicale, Hôpital Civil, CHRU/Hôpitaux Universitaires de Strasbourg, 1 place de l'Hopital, 67091 Strasbourg Cedex, France

P Kintz

M Villain

Institut de Médecine Légale, Faculté de Médecine de Strasbourg, 11 rue Humann, 67085 Strasbourg Cedex, France

C Kummerlen

P Sauder

Service de Réanimation Médicale, Hôpital Civil, CHRU/Hôpitaux Universitaires de Strasbourg, 1 place de l'Hôpital, 67091 Strasbourg Cedex, France

B Ludes

Institut de Médecine Légale, Faculté de Médecine de Strasbourg, 11 rue Humann, 67085 Strasbourg Cedex, France

A fatality involving verapamil, a calcium channel blocker agent, is presented. A 51-year old male ingested 7200 mg of sustained-release (SR) verapamil at T0 and died 40 hours later of refractory, mixed shock and multiorgan failure. The symptoms displayed during hospitalization were quite typical and involved altered consciousness, hypotension, bradycardia, atrioventricular block, metabolic acidosis and renal failure. Verapamil and its primary metabolite, norverapamil, were assayed on eight plasma and two urine samples, successively taken between the admission to the ICU (T0-4 hours) and time of death, using an original high-performance liquid chromatography/mass spectrometry (HPLC/MS) procedure with verapamil-d3 as internal standard. Plasma verapamil and norverapamil levels on admission were 0.94 and 1.36 mg/mL, respectively, then verapamil remained practically unchanged throughout the hospitalization (0.85 mg/mL at T0-40 hours). The discussion focuses on the detrimental role of SR formulations in overdose, with special emphasis on the risk of pharmacobezoar development already reported with SR-verapamil. To our knowledge, this is the first report of a verapamil fatality documented by repeated plasma measurements of the drug during the antemortem period.

Key Words: HPLC/MS • poisoning • sustained-release • toxicokinetics • verapamil


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?